PHARMACOKINETICS AND SAFETY OF A SINGLE DOSE OF ELEBSIRAN ( VIR-2218, SIRNA) SUBCUTANEOUSLY ADMINISTERED IN ADULT PARTICIPANTS WITH MODERATE RENAL IMPAIRMENT

被引：0
|
作者：
Wang, Li [1 ]
El-zailik, Asma [1 ]
Boundy, Keith [1 ]
Mao, Shenghua [1 ]
Aryal, Madhukar [1 ]
Gupta, Sneha [1 ]
Reyes, Maribel [1 ]
机构：
[1] Vir Biotechnol Inc, San Francisco, CA USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
376
引用
收藏
页码：S268 / S269
页数：2
相关论文
共 50 条
  • [1] PHARMACOKINETICS AND SAFETY OF VIR-2218 MONOTHERAPY IN ADULT CIRRHOTIC PARTICIPANTS WITH MODERATE HEPATIC IMPAIRMENT
    Wang, Li
    Chattergoon, Michael A.
    Elie, Sophia
    Wu, Pan
    Hristopoulos, George
    Gupta, Sneha
    Reyes, Maribel
    HEPATOLOGY, 2023, 78 : S581 - S582
  • [2] Pharmacokinetics and safety of the monoclonal antibody tobevibart (VIR-3434) administered as monotherapy or in combination with the small interfering RNA elebsiran (VIR-2218) in cirrhotic participants with mild hepatic impairment
    Wang, Li
    Gupta, Sneha
    Chattergoon, Michael A.
    El-Zailik, Asma
    Huang, Cheng
    Hristopoulos, George
    Reyes, Maribel
    JOURNAL OF HEPATOLOGY, 2024, 80 : S816 - S816
  • [3] Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
    Sneha V. Gupta
    Marie C. Fanget
    Christopher MacLauchlin
    Valerie A. Clausen
    Jing Li
    Daniel Cloutier
    Ling Shen
    Gabriel J. Robbie
    Erik Mogalian
    Drugs in R&D, 2021, 21 : 455 - 465
  • [4] Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection
    Gupta, Sneha, V
    Fanget, Marie C.
    MacLauchlin, Christopher
    Clausen, Valerie A.
    Li, Jing
    Cloutier, Daniel
    Shen, Ling
    Robbie, Gabriel J.
    Mogalian, Erik
    DRUGS IN R&D, 2021, 21 (04) : 455 - 465
  • [5] Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
    Vidya Perera
    Grigor Abelian
    Danshi Li
    Zhaoqing Wang
    Liping Zhang
    Susan Lubin
    Akintunde Bello
    Bindu Murthy
    Clinical Pharmacokinetics, 2022, 61 : 1405 - 1416
  • [6] Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
    Perera, Vidya
    Abelian, Grigor
    Li, Danshi
    Wang, Zhaoqing
    Zhang, Liping
    Lubin, Susan
    Bello, Akintunde
    Murthy, Bindu
    CLINICAL PHARMACOKINETICS, 2022, 61 (10) : 1405 - 1416
  • [7] EFFICACY AND SAFETY OF TOBEVIBART (VIR-3434) ALONE OR IN COMBINATION WITH ELEBSIRAN (VIR-2218) IN PARTICIPANTS WITH CHRONIC HEPATITIS DELTA VIRUS INFECTION: WEEK 24 PRIMARY ENDPOINT ANALYSIS FROM THE PHASE 2 SOLSTICE TRIAL
    Asselah, Tarik
    Streinu-Cercel, Anca
    Jucov, Alina
    Gane, Edward
    Wedemeyer, Heiner
    Lampertico, Pietro
    Chattergoon, Michael
    Chow, Sophia
    Wu, Pan
    Pilowa, Cara
    Correll, Todd
    Hwang, Carey
    Agarwal, Kosh
    HEPATOLOGY, 2024, 80 : S1987 - S1988
  • [8] Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants
    Asselah, Tarik
    Streinu-Cercel, Anca
    Jucov, Alina
    Gane, Edward J.
    Wedemeyer, Heiner
    Lampertico, Pietro
    Chattergoon, Michael A.
    Wu, Pan
    Maciejewski, Sonia
    Pilowa, Cara
    Hassani, Afshar
    Correll, Todd
    Hwang, Carey
    Agarwal, Kosh
    JOURNAL OF HEPATOLOGY, 2024, 80 : S75 - S76
  • [9] Pharmacokinetics and Safety of Single-dose Atogepant in Participants with Hepatic Impairment
    Boinpally, R.
    Jakate, A.
    Butler, M.
    Borbridge, L.
    Periclou, A.
    HEADACHE, 2020, 60 : 45 - 46
  • [10] Single-dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment
    Boinpally, Ramesh
    Weissman, Darren
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (02): : 132 - 140
12345